Generate QR code
Open Access
Subscription Access
FUNCTIONAL STATUS AND QUALITY OF LIFE DYNAMICS, HEART RHYTHM DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE DURING FUROSEMIDE AND TORASEMIDE THERAPY
https://doi.org/10.17021/2019.14.3.104.109
Abstract
The article presents the results of the research conducted to study the characteristics of changes in functional status, quality of life, frequency of supraventricular and ventricular arrhythmias in patients with chronic heart failure of ischemic origin during diuretic therapy with furosemide and torasemide. 100 patients with chronic heart failure II-IV functional class were included in the research; all the patients were divided into 2 groups, each consisted of 50 patients, depending on the diuretic drug used (furosemide or torasemide). In the first group, treatment with furosemide was carried out, in the second group treatment was carried out with torasemide. The control group consisted of 21 with chronic heart failure. They had stable effort angina of exertion I-II functional class without signs of heart failure. The following research methods were used in the work: the clinical state assessment scale by V.Yu. Marev (V.Yu. Marev scale), The Minnesota Living with Heart Failure Questionnaire on the quality of life of patients with heart failure, the 6-minute walk test. The results of the study showed that against the background of long-term treatment with diuretics, a significant improvement in the clinical condition was observed according to the clinical condition assessment scale from 8,5 to 13,7 scores with furosemide therapy and from 7,1 to 12,1 with torasemide therapy, p < 0,01, which is accompanied by a decrease in functional class of chronic heart failure in both groups according to the test results with a 6-minute walk test. When assessing the quality of life, its improvement was observed, which was reflected in the decrease in the number of scores from 71,6 to 46,4 with furosemide and from 69,7 to 40,5 with torasemide.
About the Author
K. R. Aliyeva
Scientific Research Institute of Cardiology named after J. Abdullayev, The Ministry of Healthcare of Azerbaijan Republic
Russian Federation
Russian Federation
References
1. Ageev F. T., Jubrina E. S., Gilarevsky S. R., Mareev V. Yu., Khoseva E. N., Golshmid M. V., Deev A. D., Kotkina T. I., Lukina Yu. V., Malishevskiy M. V., Masenko V. P., Rogozhkina Yu. A., Seredenina E. M., Sinitsina I. I., Suslikov A. V., Titov V. N. Sravnitel'naya effektivnost' i bezopasnost' dlitel'nogo primeneniya torasemida i furosemida u bol'nykh s kompensirovannoy serdechnoy nedostatochnost'yu. Vliyaniye na markery fibroza miokarda [Comparative efficacy and safety of long-term use of torasemide and furosemide in patients with compensated heart failure. Effect on markers of myocardial fibrosis]. Serdechnaya nedostatochnost' [Heart failure], 2013, vol. 14, no. 2 (76), pp. 55-62.
2. Asami M, Aoki J, Tanimoto S, Horiuchi Y, Watanabe M, Furui K, Yasuhara K, Sato T, Tanabe K, Hara K. Effect of long-acting loop diuretics in heart failure with reduced ejection fraction patients with cardiac resynchronization therapy. Int. Heart J., 2017, vol. 58, no. 2, pp. 211-219. doi: 10.1536/ihj.16-290.
3. Barbanoj M. J., Ballester M. R., Antonijoan R. M., Puntes M., Gropper S., Santos B., Albet C., Guglietta A. A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation. Clin. Exp. Pharmacol. Physiol., 2009, vol. 36, no. 5-6, pp. 469-477. doi: https://doi.org/10.1111/j.1440-1681.2008.05089.x.
4. Mareev V. Yu., Vygodin V. A., Belenkov Yu. N. Diureticheskaya terapiya effektivnymi dozami peroral'nykh diuretikov torasemida (diuvera) I furosemida v lechenii bol'nykh s obostreniyem khronicheskoy serdechnoy nedostatochnosti (Duel'-KHSN) [Diuretic therapy with efficacious doses of oral diuretics: torasemide (diuver) and furosemide in treating patients with acute exacerbation of chronic heart failure (CHF-DUEL)]. Serdechnaya nedostatochnost' [Heart failure], 2011, vol. 12, no. 3 (64), pp. 3-10.
5. Mentz R. J., Buggey J., Fiuzat M., Ersbшll M. K., Schulte P. J., DeVore A. D., Eisenstein E. L, Anstrom K. J., OʼConnor C. M., Velazquez E. J. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J. Cardiovasc. Pharmacol., 2015, vol. 65, no. 5, pp. 438-443. doi: https://doi.org/ 10.1097/FJC.0000000000000212.
6. Murray M. D., Deer M. M., Ferguson J. A., Dexter P. R., Bennett S. J., Perkins S. M., Smith F. E., Lane K. A., Adams L. D., Tierney W. M., Brater D. C. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med., 2001, vol. 111, no. 7, pp. 513-520.
7. Patterson J. H., Adams K. F. Jr., Applefeld M. M., Corder C. N., Masse B. R. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy, 1994, vol. 14, no. 5, pp. 514-521.
8. Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G. F., Coats A. J. S., Falk V., Gonzalez-Juanatey J. R., Harjola V. P., Jankowska E. A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J. T., Pieske B., Riley J. P., Rosano G. M. C., Ruilope L. M., Ruschitzka F., Rutten F. H., van der Meer P.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 2016, vol. 37, no. 27, pp. 2129-2200.doi: 10.1093/eurheartj/ehw128.
9. Shugushev H. H., Gaeva A. A. Vliyaniye furosemida i torasemida na variabel'nost' serdechnogo ritma i zheludochkovyye aritmii u bol'nykh s khronicheskoy serdechnoy nedostatochnost'yu, oslozhnivshey techeniye ishemicheskoy bolezni serdtsa: sravnitel'noye nerandomizirovannoye issledovaniye [Effect of furosemide and torasemide on heart rate variability and ventricular rhythm disorders in patients with chronic heart failure complicating ischemic heart disease: comparative nonrandomized study]. Ratsional'naya farmakoterapiya v kardiologii [Rational pharmacotherapy in cardiology], 2010, vol. 6, no. 4, pp. 513-517.
10. Sidorenko B. A., Preobrazhenskiy D. V., Batyraliyev T. A., Pershukov I. V., Makhmutkhodzhaev S. A. Mesto diuretikov v lechenii khronicheskoy serdechnoy nedostatochnosti. Chast' I [The place of diuretics in the treatment of chronic heart failure. Part I]. Kardiologiya [Cardiology], 2005, vol. 45, no. 8, pp. 76-83.
11. Spiridonov S. P. Indikatory kachestva zhizni i metodologii ikh formirovaniya [Life quality indicators and methodology of their development]. Voprosy sovremennoy nauki i praktiki. Universitet im. V.I. Vernadskogo [Problems of Contemporary Science and Practice. Vernadsky University], 2010, no. 10-12 (31), pp. 208-223.
Review
For citations:
Aliyeva K.R. FUNCTIONAL STATUS AND QUALITY OF LIFE DYNAMICS, HEART RHYTHM DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE DURING FUROSEMIDE AND TORASEMIDE THERAPY. Astrakhan medical journal. 2019;14(3):104-109. (In Russ.) https://doi.org/10.17021/2019.14.3.104.109
Views:
120
Email this article 